AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03665259 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pure oxygen group
Description: pre-oxygenation with 100% oxygen during induction of anesthesia
Study NCT03665259 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lower oxygen group
Description: Pre-oxygenation with 60% oxygen during induction of anesthesia
Study NCT02399644 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT
Description: ACT is a type of Cognitive behavioral Therapy (CBT) that focuses on acceptance and mindfulness. The aim is to prevent avoidance and control of negative private events such as anxiety or pain. The treatment consists of 7 weekly group sessions, 2 hours a week. The participants are given homework between sessions.
Study NCT02571777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QVM149 150/50/160
Study NCT02571777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QVM149 150/50/80
Study NCT02571777 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: QMF149 150/320
Study NCT02571777 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: QMF149 150/160
Study NCT03078023 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: swallowed sponge device
Description: Swallowed sponge: Subjects having a clinical upper endoscopy will be asked to swallow the sponge 2 hours prior to EGD
Study NCT02288611 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Date fruit - Ajwa variety
Description: Twenty-two healthy human individuals were randomly assigned to consume 7 date fruits (approx. 50g). Each arm was 21 days in duration, separated by a 14 days washout period.
Study NCT02288611 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Maltodextrin/Dextrose
Description: Twenty-two healthy human individuals were randomly assigned to consume Maltodextrin/dextrose , 40.2g. Each arm was 21 days in duration, separated by a 14 days washout period.
Study NCT02781350 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: HFHC meal
Description: 900 Cal high fat high carbohydrate fast food meal (HFHC). meal includes egg muffin and sausage muffin sandwiches and two hash browns which contain 88g carbohydrates, 51 g fat (33% saturated) and 34 g protein (carbohydrates 41%, protein 17%, and fat 42%).
Study NCT02781350 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HFHC MEAL plus Fiber
Description: 900 Cal high fat high carbohydrate fast food meal containing egg muffin and sausage muffin sandwiches and two hash browns which contain 88g carbohydrates, 51 g fat (33% saturated) and 34 g protein (carbohydrates 41%, protein 17%, and fat 42%).with FiberOne Original cereal 14 grams (half cup) each before and after the HFHC meal
Study NCT01661166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fesoterodine
Description: 4 mg
Study NCT01661166 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo
Study NCT01705964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IM epinephrine 1:1000
Description: IM epinephrine 1:1000. The dose will be 0.2 mg for subjects 20-30 kg and 0.3 mg for subjects greater than 30 kg. This will be injected intramuscularly by an ED nurse into the anterior thigh muscles of the subject using a 1 ml syringe and a 23 gauge one inch needle.
Study NCT01705964 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: No intervention
Description: A sham band-aid will be applied to the anterior thigh of subjects who are randomized to the no intervention group.
Study NCT04791787 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard weight maintaining diet
Description: Diet containing diet approximately 25-35% protein, 45-55% carbohydrate, 20- 30% fat
Study NCT04791787 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Weight maintaining isocaloric ketogenic diet
Description: Isocaloric ketogenic diet containing approximately 15-25% protein, 5-10% carbohydrate,70- 80% fat
Study NCT04791787 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Beta-hydroxy butyrate
Description: A supplement of ketone ester of beta-hydroxy butyrate
Study NCT00633308 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NxStage System One (NxStage Medical, Lawrence, MA)
Description: Each patient will be studied on 4 separate occasions. The study sessions are longer than routine daily hemodialysis therapy using the System One.
Study NCT01699412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clobetasol
Description: Rinse with a solution of clobetasol 0.05% associated to nystatin 100,000 UI/mL, for 1 minute, during 28 days
Study NCT01699412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Rinse with a solution of dexamethasone 0.1 mg/mL associated to nystatin 100,000 UI/mL, for 1 minute, during 28 days
Study NCT01788150 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary Stenting
Study NCT01788150 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coronary Stenting
Study NCT00387348 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: escitalopram oxalate
Description: escitalopram oxalate 10 mg once daily for 4 weeks
Study NCT02399644 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Participants are going to perform a training programme including aerobic exercise as well as endurance and strength training for the neck, shoulders, low back, core and leg muscles. The training is group-based and supervised by a physiotherapist two times a week, one hour a time for eight weeks. Home exercises twice a week are also a part of the intervention. It is possible to individually adjust movements and intensity to the participants' capacity if needed.
Study NCT02487953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Description: 21 mg/24 h for 2 weeks before the quit date and 12 weeks after the quit date, 14 mg/24 h for 2 weeks, and 7 mg/ 24 h for 2 weeks.
Study NCT02487953 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine patch
Description: 21 mg/24 h for 2 weeks before the quit date and 12 weeks after the quit date, 14 mg/24 h for 2 weeks, and 7 mg/ 24 h for 2 weeks.
Study NCT02487953 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENDS
Description: As needed for 1 week before the quit date and 8 weeks after the quit date, then reduced use for 4 weeks.
Study NCT02487953 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ENDS
Description: As needed for 1 week before the quit date and 8 weeks after the quit date, then reduced use for 4 weeks.
Study NCT02487953 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo patch
Description: 21 mg size for 2 weeks before the quit date and 12 weeks after the quit date, 14 mg size for 2 weeks, and 7 mg size for 2 weeks.
Study NCT02487953 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo ENDS
Description: As needed for 1 week before the quit date and 8 weeks after the quit date, then reduced use for 4 weeks.
Study NCT03323684 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quadratus lumborum block Group (QL)
Description: 20 mL of 0.375% isobaric bupivacaine for each side deposited at the posterior aspect of the quadratus lumborum muscle (QLB type 2) using ultrasound after induction of general anesthesia and 15 minutes before start of surgery
Study NCT03323684 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transversus abdominis plane Group (TAP)
Description: 20 mL of 0.375% isobaric bupivacaine for each side using ultrasound after induction of general anesthesia and 15 minutes before start of surgery
Study NCT03323684 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control group (C)
Description: No intervention will be done
Study NCT03323684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol infusion
Description: Paracetamol infusion (15 mg.kg) will be given by intravenous infusion after induction of general anesthesia.
Study NCT03323684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac analgesia
Description: In PACU Ketorolac 30 mg ampoule will be given by intravenous infusion to all cases and then every 8 hours.
Study NCT03323684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fentanyl
Description: With induction of general anaesthesia, fentanyl (1 microgram.kg) will be given. Intraoperatively, Fentanyl boluses (0.5 microgram.kg) will be given in case of increase in intraoperative mean arterial blood pressure or heart rate of more than 20% of baseline for longer than 5 minutes. Postoperatively, Fentanyl boluses (20 micrograms) will be given if VAS is more than 3 and it might be repeated after 30 minutes until VAS is ≤ 3.
Study NCT00547963 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: brief counseling
Description: baseline assessment + two 40 minute sessions of brief counseling
Study NCT03150381 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight Loss Only
Description: 24- month weight loss program (year 1: weekly in person meetings for 6 months, followed by 2 meetings per month for 3 months, then monthly for 3 months; year 2: monthly phone calls)
Study NCT03150381 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Loss Plus
Description: Participants will attend in-person weekly sessions (about 1.5 hours each) for 6 months and then twice a month for 3 months and monthly for 3 months. Sessions focus on behavioral techniques supporting healthy diet (including calorie restriction for weight loss) and achieving recommended amounts of physical activity per week. During 1-year weight loss maintenance, participants receive monthly motivational phone calls.
Study NCT03150381 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Participants receive quarterly newsletters containing generic cancer prevention messages and participate in community-wide cancer awareness educational sessions.
Study NCT01035502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elacytarabine plus idarubicin
Description: Elacytarabine 1000 mg/m2/d will be administered as a continuous intravenous infusion (CIV) in a d 1-5 q3w cycle.~Idarubicin will be administered IV at a fixed dose of 12 mg/ m2/d IV on d 1-3 q3w.~It is intended that patients receive remission-induction treatment either as two combination courses, elacytarabine 1000 mg/m2/d + idarubicin 12 mg/m2/d or one combination course, elacytarabine 1000 mg/m2/d + idarubicin 12 mg/m2/d followed by one course elacytarabine 2000 mg/m2/d single therapy.
Study NCT00710983 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Oral polio vaccine
Study NCT01697085 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sea buckthorn oil
Study NCT02571777 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: salmeterol/fluticasone
Study NCT01697085 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oil
Study NCT00394576 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based nutrition module along with usual care
Description: usual care plus Internet-based nutrition module
Study NCT00394576 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Description: usual care
Study NCT03415503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medox® Anthocyanin capsules
Description: Subjects were orally administered Medox® capsules daily for 12 weeks.
Study NCT03415503 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Medox® Anthocyanin capsules
Description: Subjects were orally administered Medox® capsules daily for 12 weeks.
Study NCT00387348 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: one placebo pill identical in appearance to the escitalpram pill once daily
Study NCT00387348 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: one placebo pill identical in appearance to the escitalpram pill once daily
Study NCT03214926 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Moving Through Glass intervention
Study NCT01932931 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: cholecalciferol (50ug)
Description: The aim of the study was to investigate the effect of high dose vitamin D3 supplementation on the muscoloskeletal system among patients treated with antidepressants due to a diagnosis of major depressive disorder
Study NCT01932931 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: cholecalciferol (50ug)
Description: The aim of the study was to investigate the effect of high dose vitamin D3 supplementation on the muscoloskeletal system among patients treated with antidepressants due to a diagnosis of major depressive disorder
Study NCT02786108 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: left gastric artery embolization
Study NCT02786108 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: healthy diet and exercise
Study NCT04779632 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Experimental: Fish Oil
Description: Participants are provided with fish oil capsules and asked to take 4 capsules of 1000 mg twice a day (in total 5.2 mg/day of long-chain n-3 fatty acids hereof 2400 mg of eicosapentaenoic acid and 1600 mg of docosahexaenoic acid) for 4 weeks.
Study NCT04779632 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Comparator: Safflower Oil
Description: Participants are provided with fish oil capsules and asked to take 4 capsules of 500 mg twice a day (containing \~ 3000 mg of linoleic acid) for 4 weeks.
Study NCT05622357 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: short course radiation therapy followed by 6 cycles of CAPOX then surgery
Description: Short course RT 5 x5 Gy followed by 6 cycles CAPOX then surgery
Study NCT01297283 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LECG first
Description: Measurement of the pacing threshold with the support of a leadless ECG
Study NCT01297283 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Programmer ECG first
Description: Pacing threshold measurements are done with the support of the programmer ECG
Study NCT02468206 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Balloon-occluded retrograde transvenous obliteration
Description: Balloon-occluded retrograde transvenous obliteration
Study NCT02468206 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic cyanoacrylate injection
Description: Endoscopic cyanoacrylate injection
Study NCT02468206 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-butyl-2-cyanoacrylate
Study NCT02468206 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lauromacrogol
Study NCT01726712 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Care
Description: Provide emotional support. Provide practical support. Support friend/family by helping him find information or help for those with HIV in the community
Study NCT03310437 — intervention group
Intervention type: PROCEDURE
Intervention: Primary PCI
Description: Primary percutaneous coronary intervention in acute myocardial infarction patients
Study NCT01233700 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Standard motivational interviewing techniques will be applied to assist subjects to consider and work to resolve any remaining concerns, doubts, or ambivalence about their decision about donating an organ to someone else.
Study NCT01233700 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Lifestyles Education
Description: Educational information will be presented to subjects in didactic form on lifestyles issues of relevance to living donors.
Study NCT01925612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin
Description: 1.2 mg/kg by IV infusion every 3 weeks for up to 6 cycles
Study NCT01925612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin
Description: 1.8 mg/kg by IV infusion every 3 weeks for up to 6 cycles
Study NCT01925612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: 375 mg/m2 every 3 weeks by IV infusion for up to 6 cycles
Study NCT01925612 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rituximab
Description: 375 mg/m2 every 3 weeks by IV infusion for up to 6 cycles
Study NCT01925612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine
Description: 1.4 mg/m2 every 3 weeks by IV infusion for up to 6 cycles (dose capped at 2 mg total)
Study NCT01925612 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vincristine
Description: 1.4 mg/m2 every 3 weeks by IV infusion for up to 6 cycles (dose capped at 2 mg total)
Study NCT00948688 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Once per day, 5 days a week for 6 weeks
Study NCT00948688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: Intravenously over 24 hours, 7 days per week during each week of radiation therapy
Study NCT00948688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Taken orally. Dose will depend upon time of enrollment and how well previous participants tolerated the drug
Study NCT03714607 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Erbium Yttrium Aluminum Garnet (Er:YAG) laser
Description: 5 Er:YAG laser therapies vaginally administered at monthly intervals
Study NCT01152307 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DVD/Booklet: Coping with Symptoms of Depression
Description: DVD and booklet that provides information about treatment choices for depression symptoms
Study NCT00524121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Oral
Study NCT00524121 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Correlative Study
Study NCT00524121 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Radiation Treatment
Study NCT01840943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAELYX
Description: CAELYX 50 mg per square meter will be administered intravenously on Day 1 of each cycle as: 60 to 90-minute infusion to the participants not undergoing pharmacokinetic (PK) evaluation and 90-minute infusion to the participants undergoing for PK evaluation.
Study NCT01840943 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topotecan HCl
Description: Topotecan 1.25 mg per square meter per day will be administered, intravenously for 30-minutes duration, on Day 1 to Day 5 of each cycle.
Study NCT00983034 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lansoprazole, amoxicillin, clarithromycin
Description: lansoprazole, 30 mg twice daily, plus amoxicillin, 0.75 g twice daily, plus clarithromycin, 250 mg twice daily, for 14 days
Study NCT02481193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisatracurium
Description: Different doses of cisatracurium pretreatment
Study NCT01458678 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Volume of colloid infusion
Description: Colloid infusion is primarily given as hydroxyethyl starch 60 mg/ml. If more than 30 ml/kg hydroxyethyl starch 60 mg/ml is given, colloid solution is changed to albumin 4% or plasma.
Study NCT01458678 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Volume of colloid infusion
Description: Colloid infusion is given primarily as hydroxyethyl starch 60 mg/ml. If more than 30 ml/kg hydroxyethyl starch 60 mg/ml is given, colloid solution is changed to albumin 4% or plasma.
Study NCT02126995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MG01CI extended-release tablet
Description: Metadoxine, MG01CI extended-release tablet taken for 6 weeks treatment. Starting with a dose of 700 mg for 2 weeks followed by a 2 weeks of 1400 mg and then 2 weeks of 700 mg or 1400 mg.
Study NCT02126995 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MG01CI extended-release tablet
Description: Metadoxine, MG01CI extended-release tablet taken for 6 weeks treatment. Starting with a dose of 700 mg for 2 weeks followed by a 2 weeks of 1400 mg and then 2 weeks of 700 mg or 1400 mg.
Study NCT02155790 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Peregrine System Infusion Catheter
Description: The ASI catheter is inserted bilaterally into the renal arteries and a specified amount of a neurolytic agent is inserted into the vessel walls.
Study NCT01773811 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Narrative Writing: Trauma-Assigned
Description: Individuals will be writing about their most traumatic life event for 3 consecutive days for 20 minutes each. Those in the assigned group will be given instructions and weekly reminders to continue to think about their most traumatic event.
Study NCT01773811 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Narrative Writing: Trauma-Spontaneous
Description: Individuals will be writing about their most traumatic life event for 3 consecutive days for 20 minutes each. Those in the spontaneous group will be given no further instructions.
Study NCT04603456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacteol fort
Description: Lacteol fort is a drug containing lactobacilli